RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat head and neck cancers
Disease control CompletedThis phase 2 trial tests a combination of two drugs—cetuximab and dalpicilib—in people with a type of head and neck cancer that has returned or spread and no longer responds to standard immunotherapy. The study includes 28 adults aged 18 to 75 whose tumors are HPV-negative. The g…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Fasting window may supercharge cancer immunotherapy
Symptom relief CompletedThis study looked at whether eating only during an 8-10 hour daytime window (without cutting calories) could help immunotherapy work better in people with advanced head and neck cancer. 29 patients were asked to follow this eating pattern, and researchers tracked how well they st…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC